secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2021-08-02T23:59:59+00:00
Accession:  0001664710-21-000048
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros Therapeutics appoints Simon Cooper as CMO effective Aug 2; Ordonez departs
--------------------------------------------------------------------------------

- Simon Cooper appointed CMO effective Aug 2, 2021; succeeds Claudia Ordonez who departed July 30.
- Dr. Cooper previously SVP/CMO at Kadmon; prior roles at Anokion, AbbVie, Sanofi, Novartis.
- Ordonez gets 9-month base salary severance, acceleration on 7,603 options, COBRA up to 9 months, $5k consulting fee.
- Cooper receives $450k base salary, 40% target bonus, option for 60,000 shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471021000048/0001664710-21-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471021000048/keros-form8xk.htm
  HTML page:      https://secwatch.observer/filing/0001664710-21-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer